Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE: DNA · IEX Real-Time Price · USD

0.860

+0.082 (10.60%)

At close: Apr 26, 2024, 4:00 PM

0.856

-0.005 (-0.53%)

After-hours: Apr 26, 2024, 7:59 PM EDT

Ginkgo Bioworks Holdings Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	944.07	1,316	1,550	380.8	495.29
Cash & Cash Equivalents	944.07	1,316	1,550	380.8	495.29
Cash Growth	-28.25%	-15.11%	307.04%	-23.12%	-
Receivables	17.9	82.47	136.14	21.91	7.68
Inventory	0	0	3.36	2.74	0
Other Current Assets	39.78	51.82	33.54	21.1	8.96
Total Current Assets	1,002	1,450	1,723	426.54	511.93
Property, Plant & Equipment	394.99	715.54	145.77	121.44	63.13
Long-Term Investments	78.57	113.73	115.23	116.42	110.98
Goodwill and Intangibles	131.98	171.25	42.95	5.15	5.7
Other Long-Term Assets	58.06	88.73	43.99	5.6	5.58
Total Long-Term Assets	663.59	1,089	347.95	248.61	185.39
Total Assets	1,665	2,539	2,071	675.15	697.32
Accounts Payable	9.32	10.45	8.19	13.89	2.44
Deferred Revenue	202.55	222.58	189.23	128.48	147.9
Other Current Liabilities	-48.01	-60.07	-62.66	-69.15	-110.26
Total Current Liabilities	163.86	172.96	134.76	73.22	40.07
Long-Term Debt	221.84	413.26	22.28	16.52	16.77
Other Long-Term Liabilities	182.5	216.83	346.57	115.36	138.62
Total Long-Term Liabilities	404.33	630.08	368.85	131.88	155.39
Total Liabilities	568.19	803.04	503.61	205.1	195.47
Total Debt	221.84	413.26	22.28	16.52	16.77
Debt Growth	-46.32%	1754.58%	34.90%	-1.49%	-
Retained Earnings	-5,290.53	-4,397.66	-2,297.93	-467.88	-341.27
Comprehensive Income	1.48	-2.63	-1.72	0	0
Shareholders' Equity	1,097	1,736	1,505	461.38	493.06
Net Cash / Debt	722.24	902.54	1,528	364.28	478.52
Net Cash / Debt Growth	-19.98%	-40.92%	319.38%	-23.87%	-
Net Cash Per Share	0.37	0.54	1.12	0.29	0.42
Working Capital	837.89	1,277	1,588	353.32	471.85
Book Value Per Share	0.56	1.03	1.11	0.36	0.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).